# Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation

> **NCT01607879** · PHASE2 · COMPLETED · sponsor: **Medical College of Wisconsin** · enrollment: 48 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Standard of care ADT + (HMB + arginine + glutamine)
- **OTHER:** Standard of care ADT

## Key facts

- **NCT ID:** NCT01607879
- **Lead sponsor:** Medical College of Wisconsin
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-03
- **Primary completion:** 2018-07
- **Final completion:** 2021-02-16
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2023-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01607879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01607879, "Use of β-hydroxy-β-methylbutyrate to Counteract Muscle Loss in Men With Prostate Cancer on Androgen Ablation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01607879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*